Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks multi-billion-dollar opportunities with planned product launches before 2030Strengthens late-stage pipeline to further support 2025-2030 net sales CAGR of 5-6% cc and mid to long term growth outlook Basel, February 27, 2026 -- Novartis AG (NYSE: NVS) today announced that it has successfully completed its acquisition of Av ...

CRANFORD, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”) today announced that it has extended the expiration date for the exchange offer by the Company to each holder of its Series C Non-Convertible Redeemable Preferred Stock, $0.01 par value per share (the “Series C Preferred Stock”), to exchange such Series C Preferred Stock for shares of Enzon’s common stock, $0.01 par value per share (the “Common Stock”). After giving effect to the extension, ...

Amneal Pharmaceuticals Q4 2025 Earnings Call Cautionary statement on forward looking statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management's intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future opera ...

Core Insights - The article highlights five US blue-chip companies that have consistently paid dividends for over 100 years, indicating their financial durability and strong management practices [1][2]. Company Summaries - **Coca-Cola (NYSE: KO)**: Founded in 1892, Coca-Cola has paid dividends since 1893, currently yielding 2.58%. It is the world's largest beverage company with over 500 brands and serves more than 1.9 billion servings daily across 200 countries. Morgan Stanley rates it Overweight with a target price of $87 [1][2]. - **Colgate-Palmolive (NYSE: CL)**: This consumer staples giant has paid dividends since 1895, yielding 2.14%. The company focuses on Oral Care, Personal Care, Home Care, and Pet Nutrition, selling products under various well-known brands. Goldman Sachs has a Buy rating with a target price of $100 [1][2]. - **Eli Lilly (NYSE: LLY)**: A healthcare company that has paid dividends since 1885, currently yielding 0.59%. Eli Lilly develops and markets pharmaceutical products, including those for cardiometabolic health and oncology. Barclays rates it Overweight with a target price of $1,350 [2]. - **Exxon Mobil (NYSE: XOM)**: This integrated oil and gas company has paid dividends since 1882, with a current yield of 2.67%. Exxon is a leader in crude oil and natural gas production and has a strong capital allocation strategy. UBS has a Buy rating with a target price of $171 [2]. - **Stanley Black & Decker (NYSE: SWK)**: The largest tool company globally, it has paid dividends for over 145 years, currently yielding 3.68%. The company offers a wide range of tools and accessories and is expected to benefit from a potential economic slowdown. Citigroup has a Buy rating with a target price of $100 [2].

Core Viewpoint - Eli Lilly's Olumiant (baricitinib) has received a positive opinion from the European Medicines Agency's CHMP for expanded use in adolescents aged 12 to under 18 with severe alopecia areata, based on promising data from the Phase 3 BRAVE-AA-PEDS study [1][2]. Group 1: Clinical Study Results - The Phase 3 BRAVE-AA-PEDS study showed that 42.4% of adolescents treated with Olumiant achieved 80% or more scalp hair coverage at 36 weeks, compared to 4.5% in the placebo group [1]. - Near-complete scalp hair coverage (90%) was achieved by 36.5% of patients on Olumiant, while only 2.3% of those on placebo reached this level [1]. - Significant eyebrow regrowth was observed in 50% of patients on Olumiant, compared to 0% in the placebo group [1]. - Eyelash regrowth was reported in 42.9% of patients treated with Olumiant, versus 14.0% in the placebo group [1]. Group 2: Regulatory and Market Implications - The positive CHMP opinion is a step towards European regulatory approval, with a decision from the European Commission expected in the next one to two months [1]. - Lilly has also submitted Olumiant for approval in the U.S. for treating severe alopecia areata in adolescents, with a decision anticipated in the second half of 2026 [1][2]. - Olumiant is already approved for adult patients with severe alopecia areata in the U.S. and Europe, marking it as the first JAK inhibitor approved for this indication [1][2]. Group 3: Safety and Efficacy Profile - The safety profile of Olumiant in adolescents aligns with previous clinical trials for other conditions, such as juvenile idiopathic arthritis and atopic dermatitis [1]. - Over 14,600 patients have participated in clinical trials involving Olumiant, with more than 1,200 being children and adolescents [1]. - The ongoing BRAVE-AA-PEDS trial includes a cohort of children aged 6 to under 12 years, further expanding the understanding of Olumiant's safety and efficacy in younger populations [1].

February 27, 2026 4Q and Full-Year 2025 Earnings Results Call © 2026 ANI Pharmaceuticals, Inc. 1 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements that are not historical facts, including statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are forward- l ...

Key TakeawaysModerna (MRNA) received a positive CHMP opinion for its mCOMBRIAX vaccine, the world’s first combination flu and COVID-19 shot recommended for authorization.Blackstone (BX) and Brookfield (BN) have emerged as lead bidders for a €8 billion unit of Volkswagen (VOW3), highlighting intense private equity interest in industrial divestments.Kazakhstan is significantly shifting its energy logistics, targeting 2.5 million tons of oil exports to Germany in 2026 while maintaining a 65 million ton flow vi ...

Group 1 - The recommendation from regulators facilitates the approval process for the shot in the European Union [1] - The company is currently under scrutiny in the United States [1]

- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorization, under exceptional circumstances, of mavorixafor for the treatment of WHIM syndrome ...

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children TARRYTOWN, N.Y. and PARIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for M ...